Kornimate/medical-research-clean huggingface dataset:
treatment of residual pockets in periodontal patients using an oscillating chitosan device

Conditions: Periodontitis

Summary: the aim of the current study was to investigate the effect of a chitosan brush on the treatment of residual pockets in patients already treated for periodontal disease. thirty-six patients with chronic periodontitis (stage ιιι, ιv) that had already completed causative therapy and exhibited at least two residual periodontal pockets ≥ 5mm that bled on probing, were randomly assigned to two groups. in the test group debridement of residual pockets was performed with ultrasonic scaler and the chitosan brush, whereas in the control group only ultrasonic scalers were used.


Eligibility criteria:
inclusion criteria: * subjects aged 18 or over * subjects diagnosed with chronic periodontitis, stage iii or iv, and had received full mouth scaling and root planning at least three months prior to baseline examination * subjects with at least two residual periodontal pockets of at least 5mm depth that bled on probing * full mouth plaques scores ≤20% exclusion criteria: * subjects that had received antibiotic therapy 6 months prior to initial examination * subjects with compromised systemic conditions * patients undergoing chemotherapy or radiotherapy * pregnant or lactating women

Keywords: residual pockets chitosan treatment of periodontitis
burn coverage of burn by tilapia fish skin

Conditions: Tilapia Fish Skin in Burn Coverage

Summary: the goal of this experimental study is to compare tfs and regular dressings as coverage for acute thermal burns. the main question it aims to answer is: is tfs effective in treating thermal burns? burn induction was done on rabbits to obtain second-degree thermal burn, followed by coverage with tfs

nile tilapia fish skin (ntfs) has been suggested as an option for biological material for the management of burns. nile tilapia fish skin also presented a large composition of type i collagen, morphology similar to human skin and high resistance and tensile extension at the break. we chose baladi rabbits for their relatively ease of handling, accommodation and resistance to surgical aggressions and infectious processes, with low mortality. however, the choice of male rabbits is due to variations in hormonal cycles in females that could intervene in the process of tissue repair. this experimental model was established to evaluate healing process and outcome results after application of tilapia fish skin on acute contact thermal that was done in order to obtain injuries with the same size and depth.

Eligibility criteria:
inclusion criteria: - healthy male one year old rabbit exclusion criteria: * female unhealthy rabbits
a phase ii study to determine the safety and efficacy of second-line treatment with metformin and chemotherapy (folfox6 or fofiri) in the second line threatment of advanced colorectal cancer

Conditions: Previously Treated Advanced Colorectal Cancer

Summary: to determine the safety and efficacy of second-line treatment with metformin and chemotherapy (folfox6 or fofiri) in the second line treatment of advanced colorectal cancer


Eligibility criteria:
inclusion criteria: * age over 18 * histologically confirmted advanced colorectal cancer * ecog ps 0-2 * expected life span more than 3months * normal bone marrow, liver, renal function exclusion criteria: * 5-fu, oxaliplatin, irinotecan or metformin allergic history * lactic acidosis, metabolic acidosis * active infection or severe neuropathy

Keywords: colorectal cancer metformin folfox6 fofiri 5fu irinotecan oxaliplatin
study the effect of upper expansion appliances on lower jaw forward projection/growth

Conditions: Overbite (Excessive) Horizontal

Summary: young children with backward positioned lower jaw/chin will be recruited to have an upper jaw expansion appliance. previous research showed that the use of similar appliances can lead to lower jaw forward growth. 60 young children aged 9-11 will be recruited to have either active or non-active wilson type upper arch expansion appliance. patients will have special x-ray (cone beam computed tomography) before and after treatment (after 9 months) of starting the treatment. after participation, routine orthodontic treatment will be continued.

previous research showed that the use of upper jaw expansion appliances can lead to lower jaw forward growth (1). 60 young children aged 9-11 with backward positioned lower jaw/chin will be recruited to have either active or non-active wilson type upper arch expansion appliance. patients will have special x-ray (cone beam computed tomography) before and after treatment (after 9 months) of starting the treatment. after participation, routine orthodontic treatment will be continued.

Eligibility criteria:
inclusion criteria: 1. class ii skeletal due to lower jaw backward projection 2. class ii malocclusion 3. early mixed dentition (all first permanent molars erupted, as well as all erupting upper and lower permanent incisors) exclusion criteria: 1. other orthodontic treatment provided 2. growth problems (craniofacial syndromes, etc.)
study to compare maternal, fetal, and infant outcomes of women with mild to moderate atopic dermatitis exposed to ruxolitinib cream during pregnancy with an unexposed control population

Conditions: Pregnancy Related; Atopic Dermatitis

Summary: this observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (mcm)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.

this study is an exposure cohort study of women within the us with ad who were exposed to ruxolitinib cream at any time during their pregnancy period, defined as up to 24 days prior to the estimated date of conception (doc) through the end of pregnancy, compared with women in the us with atopic dermatitis (ad) not exposed to ruxolitinib cream during pregnancy. the doc is estimated to occur 14 days after the last menstrual period (lmp). eligible pregnant women may self-enroll or voluntarily be enrolled by their health care provider (hcp) by calling syneos health. enrollment should occur as early in pregnancy as possible.

Eligibility criteria:
inclusion criteria: * women, aged 15 to 50 years, with confirmed diagnosis of mild to moderate ad. * ability to comprehend and willingness to give informed consent for the study; a legal minor needs parental or legally authorized representative's consent. * prospective enrollment (ie, enrollment into the registry while the pregnancy is ongoing) or retrospective enrollment (ie, enrollment into the registry within 12 months of pregnancy outcome). * information available to confirm eligibility for either the exposed to ruxolitinib cream cohort or the not exposed to ruxolitinib cream cohort. * ruxolitinib cream cohort: consisting of pregnancies in women with ad and exposure to at least 1 application of ruxolitinib cream during the pregnancy period. * nonexposed cohort: consisting of pregnancies in women with ad but not exposed to ruxolitinib cream during the pregnancy period * reporter (eg, participant, maternal hcp) contact information available to allow for follow-up. * permission to contact the participant's and her infant's hcps. exclusion criteria: * if no longer pregnant and pregnancy outcome occurred more than 12 months prior to enrollment. * current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before enrollment with another investigational medication or current enrollment in another investigational drug study. * any pregnancy that is exposed to any other jak inhibitor from 5 half-lives for the specific jak inhibitor used from lmp through the end of the first trimester for mcms or end of pregnancy for other outcomes.

Keywords: ruxolitinib atopic dermatitis pruritus eczema topical therapy jak inhibitor
randomized study comparing pre- and postoperative vs. conventional adjuvant treatment in receptor-negative patients

Conditions: Early Stage Breast Cancer

Summary: primarily, this clinical investigation compared overall survival and recurrence-free survival in patients with hormone receptor-negative breast cancer treated with pre- and postoperative chemotherapy vs. conventional postoperative treatment.


Eligibility criteria:
inclusion criteria: * patients with bioptically verified breast cancer * estrogen receptor-negative status * age: \< 70 years * who performance status \< 2 * laboratory parameters 1. hematopoiesis: \> 3500/mm3 leukocytes, \> 100,000/mm3 thrombocytes 2. renal function: creatinin \< 1.5mg% 3. hepatic function: got max. 2.5 x unl 4. bilirubin: \< 2.0 mg % 5. metabolic parameters: na, ca, k in normal range * \</= 4 weeks interval since surgery * informed consent exclusion criteria: * patients with locally inoperable cancer, m1 * other preoperative tumor-specific radiotherapy, chemotherapy or endocrine treatment * pregnancy or lactation * general contraindication against cytostatic treatment * t4 cancer; inflammatory disease, simultaneous or sequential bilateral breast cancer * lacking compliance or understanding of disease * serious concomitant disease * second carcinoma or status post second carcinoma (except for treated squamous cell carcinoma of the skin or cervical carcinoma in situ)

Keywords: cyclophosphamide methotrexate fluorouracil epirubicine breast cancer
intelligent pain management system for assessing pain in cancer patients

Conditions: Pain; Neoplasms

Summary: the purpose of this study is to determine whether the intelligent pain management system (ipms) could make recording and interfering pain timely among cancer patients with pain. the system's usability, feasibility, compliance, and satisfaction will also be assessed.

research indicate that over one-third of cancer patients experienced cancer pain, which is known as a major reason leading to lower quality of life of the patients.in this present study, the investigators aim to design, develop, and test the feasibility of a low cost, conveniently implemented mobile application to facilitate real-time pain recording and timely intervention among chinese cancer patients with pain. this system evaluate real-time pain and karnofsky performance status（kps）scores for quality of life, and to generate an action plan to visit the physician or to adjust pain medication dosage when the pain threshold is reached. the investigators study is to test this system's effectiveness.

Eligibility criteria:
inclusion criteria: * the patient was able to read chinese and use smart phones; * the patient was diagnosed with cancer and has self-reported cancer pain within a month prior to the study; * the patient was being seen on a regular basis by the oncology team; * the patient was under standard analgesia treatments; * the patient was estimated to have over 3 months survival time. exclusion criteria: * the patients who self-reported to have severe cognitive impairments or major comorbid illnesses that would interfere with pain assessment.

Keywords: cancer pain mobile applications
the diagnosis and mechanism of pleural effusion

Conditions: Pleural Diseases

Summary: the diagnosis, treatment and mechanism of pleural diseases

the diagnosis and treatment of benign and malignant pleural effusions, the mechanisms of pleural diseases

Eligibility criteria:
inclusion criteria: patients with pleural effusion, who has not been treated exclusion criteria: patients with pleural effusion, who has already been treated
can ccta technicians provide accurate interpretation of findings in patients presenting to the ed in after hours?

Conditions: Coronary Artery Disease

Summary: coronary computed tomographic angiography (ccta) is emerging as the diagnostic test of choice in chest pain patients with low to intermediate probability of coronary artery disease (cad). qualified ccta readers may not be available around the clock in most centers, limiting the use of ccta. this study aimed to determine if well-qualified ccta technicians can provide initial accurate diagnosis to guide initial management and triage of such patients


Eligibility criteria:
inclusion criteria: * all patients referred for elective ccta to assess coronary artery disease exclusion criteria: * patients with previous coronary revascularization procedures (pci or cabg).

Keywords: ccta interpretation technicians experts comparison
efficacy of active versus passive methods in chronic venous insufficiency

Conditions: Chronic Venous Insufficiency

Summary: the aim of our study was to compare the effectiveness of active and passive practices in patients with cvi.

volunteers who have been diagnosed with venous insufficiency according to the criteria of inclusion, who applied to cardiovascular surgery department will be included this study. participants will be randomly allocated 3 groups using the 'research randomizer' website. in all groups, a common evaluation protocol will be applied to the patients. compression therapy will be applied to the first group. active treatment in addition to compression therapy will be applied to the second group. passive treatment in addition to compression therapy will be applied to the third group.

Eligibility criteria:
inclusion criteria: * diagnosis of venous insufficiency with duplex ultrasonography * classification of ceap (clinical-etiological-anatomical-pathological) used in venous insufficiency is c3-c4-c5-c6 * ankle-brachial index (abi) is less than 0.7 * possibility to communicate in written and verbal in turkish * have a level of cognitive ability to understand the instructions given exclusion criteria: * presence of deep vein thrombosis * ulceration or open burn wound in lower extremity greater than 4 cm * presence of infected ulceration * cardiorespiratory insufficiency * orthopedic, rheumatologic or neurological comorbidities restrain the exercise in the lower extremity * presence of a psychiatric illness requiring the use of prescribed medicines

Keywords: exercise compression neuromuscular electrical stimulation massage
the application of pleth variability index in continuous monitoring the volume status of intraoperative patients

Conditions: Hemodynamic Monitoring

Summary: to assess the value of using pleth variability index(pvi) to monitor the patient's intra-operative volume status continuously by observing the application of stroke volume variation(svv) and pvi and their correlation in patients undergoing intestinal tumor surgeries.

objective: to assess the value of using pvi to monitor the patient's intra-operative volume status continuously by observing the application of stroke volume variation(svv) and pleth variability index(pvi) and their correlation in patients undergoing intestinal tumor surgeries. methods: 50 patients undergoing elective intestinal tumor surgery were enrolled, asaⅰ-ⅲ, aged 18-65 years. after the induction of general anesthesia, cardiac index(ci), cardiac output(co), stroke volume variability(svv), stroke volume index(svi) were monitored with vigileo system, while pleth variability index(pvi) and perfusion index(pi) were monitored with massion radical 7 system. during the surgery, goal directed fluid therapy was conducted according to the data of ci、svi and svv. heart rate(hr), mean arterial pressure(map), central venous pressure(cvp), co, ci, svi, svv, pi, pvi were recorded while after the induction of anesthesia(t1), making surgical incision(t2), performing intestinal anastomosis(t3) and closing the abdominal incision(t4). and we calculate the correlation of svv and pvi using pearson correlation analysis at different time points.

Eligibility criteria:
inclusion criteria: * patients undergoing elective intestinal tumor surgery * american society of anesthesiologists (asa) physical status of grade i-ⅲ * aged 18-65 years * bmi 18\~30kg/㎡ exclusion criteria: * patients under 18 years or above 65 years * patients with severe aortic regurgitation * patients with permanent cardiac arrhythmias * patients with intra-aortic balloon pump * patients with severe pulmonary disease * patients undergoing emergency surgery

Keywords: pleth variability index stroke volume variation perfusion index intraoperative intestinal tumor
app-delivered sleep therapy for older individuals with insomnia

Conditions: Insomnia

Summary: this randomised, open, parallel controlled trial aims to compare the efficacy of a digital brief behavioural therapy for insomnia (dbbti) against online sleep health education on insomnia symptom severity in older adults aged 60 years and over. the trial will be totally online with participants recruited from the community across australia.

insomnia is a highly prevalent sleep disorder affecting up to 10% of the adult population and reports of over 40% in the older population. current insomnia treatments focus heavily on symptom management with cognitive behavioural therapy for insomnia (cbti), in both digital and face-to-face form as the recommended first-line treatment. despite the strong evidence for digital cbti, there are a lack of data related to older people and whether digital brief behavioural therapy is efficacious in this population. the investigators will conduct a fully online study comparing 6-weeks of digital brief behavioural therapy for insomnia (dbbti) against online sleep health education. participants will be recruited, screened and determined eligibility and consent will be conducted online. thereafter, participants will be randomly allocated to either dbbti delivered via a mobile application called sleepfix or wait-listed control. the sleepfix app delivers sleep restriction therapy using a 4 stage approach to improve sleep efficiency. the control will consist of 3 online sleep health education modules provided bi-weekly with information about sleep and sleep hygiene without any specific insomnia therapy. participants will be recruited using social media and directed to a website to determine eligibility and then provided access to either the dbbti (sleepfix) or the control with a link to the first online module. at baseline, all participants will complete self-reported measures of insomnia, sleep, fatigue, sleepiness , anxiety, depression, quality of life, cognition and digital health literacy. these will be repeated at follow-up at weeks 8, 16 and 26.

Eligibility criteria:
inclusion criteria: 1. older adults aged ≥ 60 years 2. able to give informed online consent 3. insomnia severity index ≥ 10, including a score of 3 in at least one of the first three items (nocturnal symptoms). 4. english fluency 5. access to a smartphone and willingness/proficiency to use a mobile app exclusion criteria: 1. shift-workers 2. travel to a destination with \>2 hours time-difference (within 30-days) 3. serious medical and/or psychiatric illnesses/disorders or self-harm risk (patient health questionnaire-9, item 9, 1+ score of risk of suicidal ideation) 4. diagnosed sleep disorders other than insomnia 5. regular sleep medications or sleep devices (\>2 times a week over last 6 months) 6. currently receiving or previously received (within the last 12 months) psychotherapy for insomnia including cognitive behavioural therapy (cbt). 7. drive for work/operate heavy machinery

Keywords: sleep digital older people brief behavioural therapy
a comparison of dfd01 spray versus vehicle spray in subjects with moderate psoriasis

Conditions: Psoriasis

Summary: the objectives of this study are to compare the efficacy and safety of dfd01 spray to vehicle spray for topical treatment of moderate plaque psoriasis


Eligibility criteria:
inclusion criteria: subjects must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis. subjects with psoriasis involving 10 to 20% bsa, not including the face, scalp, groin, axillae and other intertriginous areas. subjects must have an iga grade of 3 (moderate) at the baseline visit exclusion criteria: current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis). presence of pigmentation, extensive scarring, or pigmented lesions or sunburn which could interfere with the rating of efficacy parameters. history of psoriasis unresponsive to topical treatments. history of organ transplant requiring immunosuppression, hiv, or other immunocompromised state. use within 180 days prior to baseline visit of biologic treatment for psoriasis (e.g., infliximab, adalimumab, etanercept, ustekinumab, or alefacept). have received treatment for any type of cancer within 5 years of the baseline visit except skin cancer and cervical cancer (in situ) are allowed within 1 year of the baseline visit. use within 60 days prior to the baseline visit of: 1) immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea) or 3) oral retinoids (e.g., acitretin, isotretinoin). use within 30 days prior to the baseline visit of: 1) systemic steroids, 2) puva therapy, 3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine), or 4) uvb therapy. inhaled, intraocular, and intranasal steroids are allowed. use within 14 days prior to the baseline visit of: 1) topical antipsoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene), 2) topical retinoids (e.g., tazarotene, tretinoin) or 3) topical corticosteroids. require use of beta blockers, lithium, ace inhibitors, and/or nsaids (indomethacin, ibuprofen, aspirin, naproxen) with a medical history that these medications affect the subject's psoriasis, except if the subject has been using the medication routinely during the 180 days prior to the baseline visit, these medications are allowed.
determination of risk factors of ventricular arrhythmias (vas) after implantation of continuous flow left ventricular assist device with continuous flow left ventricular assist device (cf-lvad)

Conditions: Severe Cardiac Insufficiency

Summary: determination of risk factors of ventricular arrhythmias (vas) after implantation of continuous flow left ventricular assist device in order to characterize which patient requires icd implantation in primary prevention.


Eligibility criteria:
inclusion criteria: * patient above 18 years old * patients with cf-lvad with or without icd exclusion criteria: * patients subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty

Keywords: left ventricular assist device ventricular arrhythmias implantable cardioverter-defibrillator